@FierceBiotech: Our 1st EuroBiotech Report: Merck KGaA R&D chief exits, Sobi drug flops in PhIII, Adaptimmune gets full-time CEO. Report | Follow @FierceBiotech
@JohnCFierce: Novartis is using Twitter to support its R&D team at adcomms? Social media won't substitute for another serelaxin trial. More | Follow @JohnCFierce
@DamianFierce: Syndax swings for a $69M IPO with 'breakthrough' drug in tow. News | Follow @DamianFierce
@EmilyMFierce: Report: U.S. can do more to support global health R&D. Article via FierceBiotech Research | Follow @EmilyMFierce
> Exact Sciences ($EXAS) won an FDA panel's unanimous recommendation for its stool-based colorectal cancer diagnostic. News
> Roche ($RHHBY) won European approval for a subcutaneous version of the cancer drug Rituxan. Story
@FierceMedDev: An analyst thinks Smith & Nephew should split into three pieces, and investors loved the idea. Story | Follow @FierceMedDev
@MarkHFierce: Check out FierceBiotech's debut EuroBiotech report. Report | Follow @MarkHFierce
@MichaelGFierce: Small, drug-releasing battery could dissolve completely over time. Article via FierceDrugDelivery | Follow @MichaelGFierce
@EmilyWFierce: GN Store Nord's U.S. customer base gets a boost thanks to its bluetooth-like hearing aid. Article | Follow @EmilyWFierce
> In Ohio, Steris slashes jobs and plans to close a plant. More
> Exact Sciences wins unanimous FDA committee approval for its colon cancer Dx. News
> NeuroSigma brings on two Amgen execs to bolster its finance team. Item
Pharma News
@FiercePharma: Top-read FP story yesterday: Merck, GlaxoSmithKline halt copay help for Obamacare patients. Story | Follow @FiercePharma
@TracyStaton: RT: Just out: today's full issue of FiercePharmaMarketing. More | Follow @TracyStaton
@EricPFierce: FDA's Woodcock throws cold water on research that found foreign-made generics of Lipitor tainted. Article | Follow @EricPFierce
@CarlyHFierce: Check out FierceBiotech's new EuroBiotech report, which will run every Friday from here on out. Report | Follow @CarlyHFierce
> Roche nabs European approval for time-saving formulation of Rituxan. More
> Hospira puts shareholder lawsuit behind it with $60M settlement. News
> Regeneron clears roadblock for new plant in Irish tax haven. Story